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Abstract
The inclusion of health-related quality of life (HRQoL) as an outcome measure in cystic ﬁbrosis (CF) clinical trials can supply important
patient-reported information not captured by other endpoints. Both an appropriate HRQoL measure and sound methodology are required
in order to draw valid inferences about treatments and HRQoL. This paper provides the current consensus of the HRQoL Outcomes
Group. Particular consideration has been given to the appropriateness of measurement scales, the rationale for including speciﬁc domains as
endpoints, the importance of considering baseline ceiling effects and the difﬁculties of data interpretation. Guidance is provided on HRQoL
measurement in National and European CF clinical trials.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Health-related quality of life (HRQoL) was established
as a paradigm to include the patients’ perspective in clin-
ical practice and research. Typically, HRQoL is deﬁned as
a multidimensional construct comprising (at least) physical,
psychological and social well-being and functioning as per-
ceived by the individual. The inclusion of HRQoL as an
outcome measure in cystic ﬁbrosis (CF) clinical trials is be-
coming more common. Both an appropriate HRQoL measure
and sound methodology are required in order to draw valid
inferences about treatments and HRQoL [1,2].
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1.1. Why is HRQoL important in clinical trials?
Asking the patient “how they are” or about the effec-
tiveness of treatments is nothing new. HRQoL instruments,
however, can provide a formal, standardised, valid and reliable
way of gaining the patients’ perspective as to the beneﬁts
and limitations of a speciﬁc intervention. Regulatory author-
ities and Good Clinical Practice (GCP) guidelines require
the inclusion of HRQoL in clinical trials as an additional
outcome parameter [3]. HRQoL can provide “added value”
as it can supply information not captured by other endpoints.
The correlations between clinical variables and HRQoL are
often poor. Furthermore, there are some things that only the
patient can know (for example, fatigue, nausea). HRQoL may
be informative as an efﬁcacy measure, but it is potentially also
a safety measure and for these reasons HRQoL is becoming
important in labelling claims.
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2. Considerations for measuring HRQoL in clinical trials
In the past HRQoL has been indiscriminately applied
and abused. There has been a general lack of expertise
and knowledge among trial investigators. HRQoL has been
considered easy to measure and/or not too important. This
approach has resulted in poor data quality (and potentially
unreliable claims being made about treatments). This report is
not intended to deter researchers from measuring HRQoL in
clinical trials. The aim is to outline important issues in order
to improve practice, so that those who do measure HRQoL in
trials can produce scientiﬁcally and clinically valid results.
2.1. Measurement scales
There has been little consensus on how to measure
HRQoL in CF at a conceptual or operational level. HRQoL
instruments provide different information, even for similarly
named domains (for example, social functioning can refer to
a variety of concepts), and there is no “gold standard”. The
diversity of instruments and deﬁnitions of HRQoL (deﬁned by
the items that make up the scale) have produced inconsistent
ﬁndings in CF [4]. Different types of scales have previously
been employed and include: global rating of change, ad hoc,
generic (SIP, NHP, SF36; CHQ, PedsQL), utility (QWB,
EuroQoL), non standardised proﬁles (SEIQoL), respiratory
(CRDQ, SGRQ) and CF speciﬁc scales (CFQ [5–9], CFQoL
[10], FLZ-CF [11], DISABKIDS [12])1. Only the CFQ has
scales for both children and adults. Apart from CF speciﬁc
scales, the only scales that have CF psychometric evaluation
data for investigators to consult are the SF36 and CRQ
[13,14]. When trying to evaluate change in a trial, stringent
reliability and validity criteria are paramount. Thus far, only
the respiratory scale of the CFQ has been approved by the
US Food and Drug Administration (FDA) for use as an
endpoint in trials. It is noteworthy that it is the CFQ domain
(adolescent and adult) with the most acceptable intraclass
correlation coefﬁcient for test-retest reliability. The scale
captures perceived respiratory function/symptoms which is
only one aspect of the much broader construct of HRQoL.
The International Society for Quality of Life (ISOQoL)
Efﬁcacy Working Party and the FDA have provided several
recommendations concerning HRQoL instruments [3]. First,
investigators should examine the psychometric data for an
instrument to ensure that it meets their requirements. It is
essential that an instrument’s psychometric data are robust
before the instrument is used in a trial. Construct validity,
internal reliability, known groups validity and especially test-
retest reliability must be strong. Second, a full psychometric
1 SIP = Sickness Impact Proﬁle, NHP = Nottingham Health Proﬁle, SF-36
= Short-Form 36, CHQ = Child Health Questionnaire, PedsQL = Pediatric
Quality of Life Inventory, QWB = Quality of Wellbeing Scale, SEIQol =
Schedule for the Evaluation of Individual Quality of Life, CRDQ = Chronic
Respiratory Disease Questionnaire, SGRQ = St George’s Respiratory Ques-
tionnaire, CFQ = Cystic Fibrosis Questionnaire, CFQoL = Cystic Fibrosis
Quality of Life Questionnaire, FLZ-CF = Questions on Life Satisfaction–CF
speciﬁc.
evaluation should be undertaken with cultural translation (es-
pecially construct validity and test-retest reliability). Third,
scales should be revised for developments in the disease to
ensure that they remain valid. CF disease has “evolved” and
since the CF HRQoL scales were developed several years ago
there has been a signiﬁcant increase in survival, with greater
opportunities for employment, relationships and parenting, to-
gether with an increase in CF related conditions (e.g. diabetes,
osteoporosis), new medicines and treatment burden.
2.2. HRQoL measurement should be theoretically driven.
Investigators should have a rationale for including all
outcomes in a trial and patient reported outcomes are no
exception. All HRQoL domains that make up an instrument
should be carefully considered to identify the additional
information that each domain brings to the trial. Investigators
should check that the items in speciﬁc domains are valid for
the purposes of the trial. They should be able to provide a
rationale for the inclusion/exclusion of speciﬁc domains as
endpoints. Pilot studies can be used to inform the trial as
to which domains are important in addition to the size and
variation of change(s) anticipated. Ideally, a priori hypothesis
testing should be undertaken.
2.3. Ceiling effects should be considered
Many people with CF report a good HRQoL even when
they have severe disease. It is not uncommon to have
relatively large numbers of patients scoring very highly on
some HRQoL domains at baseline. These ceiling effects are
important because investigators are presumably looking for
a change, usually an improvement in HRQoL. Therefore,
there must be the potential to demonstrate improvement if
an improvement occurs. Using baseline HRQoL scores as
inclusion/exclusion criteria should be considered especially if
HRQoL is the primary outcome. If HRQoL is a secondary
outcome, a sample size calculation or the analysis and
interpretation of results needs to take into account the
subgroup of patients who would not be expected to respond.
2.4. Data analyses and interpretation
It is a high hurdle to expect a drug or non-pharmacological
intervention to improve all HRQoL domains in a scale with
wide ranging concepts. If 10 domains in a scale are measured
and only 1 or 3 or 6 change – how should these data be
interpreted? Can it be claimed that HRQoL has improved?
In the CF literature there are claims made that a treatment
improves HRQoL when only 1 of many domains that were
measured actually improved. Theoretically driven data can
remove this interpretation difﬁculty, as investigators will
already have an a priori hypothesis for the domains to be
measured in the trial.
The interpretation of the results should not be based
solely on p values, especially if HRQoL is a secondary
outcome, when the trial tends not to be powered for HRQoL.
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This presents difﬁculties for HRQoL interpretation. The data
should be described and the clinical importance of the
ﬁndings should be discussed. Knowledge of what constitutes
a clinically important difference is helpful, although the
minimal clinical important difference (MCID) is not without
problems. For example, there can be confusion over the
interpretation of individual or population MCIDs.
A potential way forward is to measure outcomes in terms
of “responders”. A responder is a person for whom the
treatment is deemed to have been successful. Responder
criteria are the rules which determine whether a person is a
responder. The criteria may vary from one patient subgroup to
another, for example, dependent on the severity of the disease
and/or the patient’s symptoms. When designing such a trial,
investigators need to deﬁne: (a) what they expect the treatment
to do, (b) the population expected to respond to treatment,
and (c) the criteria deﬁning a responder. The report should
compare the proportions of responders in each treatment arm.
2.5. Combining data (children and adults)
There is a relatively small population of CF patients. As
a result, data from children and adult patients have been
combined in analyses, often when it was inappropriate to do
so. Investigators need to ensure that child and adult domains
with the same name (e.g. physical function) are measuring the
same concept and that the number and content of the items are
comparable. This is especially important in long term trials;
investigators need to be sure that if an adolescent enters a trial
and is reassessed as an adult – that the adolescent and adult
scales are equivalent. Currently, there are no comparable CF-
speciﬁc scales for children and adults. Therefore, data for chil-
dren and adults should not be combined in a single analysis.
3. Current consensus of the HRQoL Outcomes Group
Agreement was reached on a number of issues reﬂecting
the use of HRQoL in CF trials currently and in the future.
• The use of HRQoL should be theoretically driven.
• A CF speciﬁc scale should be used where possible.
• Existing CF scales are good at describing HRQoL and
for use in clinical practice. Further consideration of their
suitability and value in clinical trials is warranted.
• Research may continue with available measures that best
meet the criteria set out below. At the same time, for
European trials, we should ensure instrument development
that will meet optimal clinical trial criteria.
• At present it is feasible to measure HRQoL in:
(a) A national trial with adults or children, where scales
exist that have robust psychometric properties (includ-
ing construct validity and test-retest reliability).
(b) In international trials different translations of a mea-
sure could be used, but stratiﬁcation by country would
be required where translations were not direct copies
of the original or agreement between the measures not
demonstrated.
(c) At present, HRQoL should not be measured in Eu-
ropean trials where both child and adult scores are
combined for the purposes of data analysis.
• If possible, the primary source of information should be
the patient. Who reports (patient or proxy), when and how
often, will depend on the nature of the trial, but careful
consideration should be given to these issues.
• Using current developmentally appropriate scales, children
may report HRQoL reliably and consistently from the age
of 8 years. Further study should look at possible ways
of assessing HRQoL in children younger than 8 years. In
children, the collection of self-reports and parent/caregiver
reports may provide additional information, especially
regarding the observable aspects of HRQoL such as
physical function. These responses should not be regarded
as interchangeable and/or combined in data analysis.
• Scales should be short. (It is unethical to overburden
the patient; it may cause them to drop out of a trial or
compromise data quality).
• Ceiling effects should be considered and inclusion/exclu-
sion criteria deﬁned.
• Patient responses tend to be more reliable if focusing on
their present state rather than on longer recall periods.
However, the time-frame should be compatible with the
anticipated effect of the intervention to allow potential
changes in HRQoL to be determined.
• Trial investigators should seek advice on HRQoL measure-
ment, analysis, interpretation and data reporting.
4. Conclusion
HRQoL measurement, if undertaken appropriately, can
provide a standardised, valid and reliable way of gaining
the patients’ perspective as to the beneﬁts and limitations of
a speciﬁc intervention. It can supply important information
not captured by other endpoints. The current consensus of
the HRQoL Outcomes Group should provide guidance, and
help researchers avoid the many pitfalls, regarding HRQoL
measurement in National and European CF clinical trials.
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